Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 16Gynecologic 10Gastrointestinal 9Tumor-Agnostic 6Genitourinary 6Other solid neoplasm 4Head & Neck 2CNS 2Breast 2Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Solid Tumors 1Patients With Any Advanced Solid Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumour 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × nintedanib × Other solid neoplasm × Clear all
NCT02856425 2026-01-20

PEMBIB

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Completed
196 enrolled
Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT02568449 2021-12-09

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01349296 2016-05-20

BARIS

University of Cologne

Phase 1 Completed
18 enrolled
Other solid neoplasm

Solid Tumors

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
61 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡